The study, sponsored by the Foundation for Innovative New Diagnostics, aims to evaluate the effectiveness, feasibility, acceptability, and cost of continuous versus intermittent use of CGMs among individuals with Type 1 diabetes in Kenya. Given the increasing prevalence of diabetes in low- and middle-income countries (LMICs) and the potential for CGMs to improve patient outcomes, this study could inform clinical models for integrating CGMs into standard diabetes care. The findings may enhance market access for CGM manufacturers and influence pricing strategies, particularly in LMICs where cost is a significant barrier. The collaboration with local diabetes management centers and charitable trusts suggests a strong commitment to addressing healthcare disparities, which may enhance the sponsor's reputation and foster partnerships in future initiatives.